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Prostaglandin E2 As a Modulator of
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Department of Microbial, Biochemical and Food Biotechnology, University of the Free State, Bloemfontein, South Africa
Viral infections are a major cause of infectious diseases worldwide. Inflammation and the
immune system are the major host defenses against these viral infection. Prostaglandin
E2 (PGE2), an eicosanoid generated by cyclooxygenases, has been shown to modulate
inflammation and the immune system by regulating the expression/concentration of
cytokines. The effect of PGE2 on viral infection and replication is cell type- and
virus-family-dependent. The host immune system can be modulated by PGE2, with
regards to immunosuppression, inhibition of nitrogen oxide (NO) production, inhibition
of interferon (IFN) and apoptotic pathways, and inhibition of viral receptor expression.
Furthermore, PGE2 can play a role in viral infection directly by increasing the production
and release of virions, inhibiting viral binding and replication, and/or stimulating viral
gene expression. PGE2 may also have a regulatory role in the induction of autoimmunity
and in signaling via Toll-like receptors. In this review the known effects of PGE2 on the
pathogenesis of various infections caused by herpes simplex virus, rotavirus, influenza
A virus and human immunodeficiency virus as well the therapeutic potential of PGE2 are
discussed.
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INTRODUCTION
Viruses are small infectious agents that cause disease in all forms of life (Koonin et al., 2006).
Based on their genomic material, they are classified as double-stranded (ds) DNA viruses, single-
stranded (ss) DNA viruses, dsRNA viruses, (+)ssRNA viruses, (−)ssRNA viruses, ssRNA- reverse
transcriptase (RT) viruses, and dsDNA-RT viruses (Baltimore, 1971).
To protect themselves from infection by viruses, hosts evolved immune systems (Janeway et al.,
2004) consisting of many barriers and biological processes (Delves and Roitt, 2000). The immune
system can be subdivided into innate immunity and adaptive immunity. The innate immunity is
trigged when pathogens are identified by their pathogen associated molecular patterns (PAMPs) or
when cells signal in response to damage, injury, or stress (Takeuchi and Akira, 2009).Although the
innate system is non-specific and does not confer long-lasting protection (Mackay et al., 2000) it is
the major defense mechanism against pathogens in most organisms (Litman et al., 2005). It consists
of physical and chemical barriers including phagocytes and dendritic cells (DC), inflammation,
the complement system, and natural killer cells. In contrast, the adaptive immunity relies on
antigens and is highly specific to pathogens or pathogen-infected cells (Dörner and Radbruch,
2007). Lymphocytes are key role players in adaptive immunity and include both T cells and B cells
(Janeway et al., 2004). Of the various components of the immune system the following are critical
in clearance of viral infections; natural killer cells, interferons, dendritic cells, B cells, and T cells
(Aoshi et al., 2011).
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The immune system can be modulated by various
factors including prostaglandins (PGs) (Harris et al., 2002).
Prostaglandins are lipid molecules, derived from arachidonic
acid (AA) and are produced by cyclooxygenase (COX), and PG
synthases (Phipps et al., 1991). One of the most studied PGs
is prostaglandin E2 (PGE2) which is produced by many cells
including fibroblasts, macrophages and some malignant cells
(Harris et al., 2002). PGE2 regulates various processes in the
body via PGE2 receptors (EP1–EP4) (Sugimoto et al., 2000).
Both the innate and adaptive immunity can also be regulated by
the levels of PGE2, which can either have adverse or beneficial
effects on the immune system’s ability to fend off pathogens
(Kalinski, 2012). This review focuses on the regulatory role of
PGE2 on the immune system in the course of some well- viral
infections caused by herpes simplex virus, Epstein-Barr virus,
rotavirus, influenza A viruses, human immunodeficiency virus
and hepatitis B virus, and the development of related potential
therapies for the treatment of these infections.
PRODUCTION AND FUNCTION OF PGE2
Prostaglandins are eicosanoids that are produced by nearly all
mammalian cells (Park et al., 2006). They are not stored within
cells but rather produced in response to specific trauma, signaling
molecules or stimuli such as infections (Smith, 1989; Funk,
2001). PGE2 is the most abundant prostanoid (Serhan and Levy,
2003) in the mammalian body and under normal physiological
conditions and plays a role in regulation of immune responses,
blood pressure, gastrointestinal integrity, fertility (Ricciotti and
FitzGerald, 2011), and inflammation (Davies et al., 1984).
Biosynthesis of PGE2
Phospholipase A2, the Rate-Limiting Enzyme in PGE2
Synthesis
PGE2 synthesis is initiated with the liberation of AA (a
polyunsaturated fatty acid) from membrane phospholipids, by
phospholipase A2 enzymes (PLA2) (Funk, 2001) (Figure 1A).
Phospholipase A2 enzymes are divided into three major
classes: Secreted PLA2 (sPLA2), intracellular group VI calcium-
independent PLA2 (GVl iPLA2) and group IV cytosolic PLA2
(GIV cPLA2) (Murakami and Kudo, 2004). While all PLA2
enzymes can release AA from membrane phospholipids, only
cPLA2α (a family member of GIV cPLA2) performs this reaction
as a primary function (Leslie, 2004; Murakami and Kudo, 2004).
Cytosolic phospholipase A2α has been found in most cells and
tissues and is highly specific for the sn-2 bond of AA.
Production of PGH2, the Precursor to Prostanoids
Cyclooxygenases (Figure 1C) are membrane-bound heme-
containing glycoproteins that have two major functions,
namely the addition of a 15-hydroperoxy group to AA to
form prostaglandin G2 (PGG2) and the reduction of the
nascent hydroperoxy group of PGG2 to form prostaglandin
H2. Cyclooxygenase has two isoforms COX-1 (constitutively
expressed) and COX-2 (inducible). Although they are similar
in structure and function, COX-2 utilizes endogenous AA while
FIGURE 1 | The biosynthesis pathway of PGE2. (A) Production of PGE2 is
initiated with the liberation of AA by cPLA2. Arachidonic acid can then enter
one of three pathways. (B) Lipoxygenase (LOX) converts AA to
hydroperoxyeicosatetraenoic acid (HPETE) which is converted to leukotriene
A2 (LTA2) and is further converted in the remainder of the leukotriene family
(B4–E4) which are mainly responsible for lipid signaling. (C) Cytochrome P450
can also use AA as substrate which subsequently produces 16, 20-
hydroxyicosatetraenoic acid (HETE) and 14, 15-epoxyeicosatrienoic acid (EET)
which function in autocrine and paracrine signaling. (D) Arachidonic acid is
converted to PGH2 by die COX isoenzymes. (E) Prostaglandin H2 is the
precursor for all the other prostaglandins and can be converted into PGE2 (via
PGE2 synthase [cPGES, mPGES-1 and mPGES-2)], PGD2 (PGD2 synthase),
PGI2 (Prostacyclin synthase), TXA2 (TX synthase) which functions as a
vasoconstrictor. (F) PGF2α can be produced from PGH2 directly by
endoproxide reductase or form PGE2 via 9-ketoreductase. Adapted from
Jenkins et al. (2009).
COX-1 uses AA derived from exogenous sources such as dietary
intake (Park et al., 2006).
Prostaglandin E2 Synthases
Prostaglandin H2(PGH2) is the substrate for prostaglandin E
synthases (PGES) which produces the more stable prostanoid,
PGE2 (Zurier, 2014) (Figure 1D) as well as for prostanoid
synthases (Figure 1E). The production of PGE2 requires at least
three PGESs, microsomal prostaglandin E synthase-1 (mPGES-
1), mPGES-2 and cytosolic prostaglandin E synthase (cPGES)
(Figure 1E). For a detailed review on PGES the reader is referred
to Park et al. (2006).
Degradation
PGE2 is rapidly degraded in vivo by 15-hydroxyprostaglandin
dehydrogenase and is therefore rapidly removed from tissues and
circulation (Förstermann and Neufang, 1983; Tai et al., 2002).
Prostaglandin E2 Transport
Since PGs are produced intracellularly they need to be secreted
to exert their extracellular effects (Park et al., 2006). The original
Frontiers in Physiology | www.frontiersin.org 2 February 2017 | Volume 8 | Article 89
Sander et al. PGE2 in Viral Infections
prevailing notion was that newly synthesized PGs simply exited
the cell via passive diffusion, as the electronegative interior of the
cell favors the diffusion out of the cell (Schuster, 2002). However,
the kinetics behind PG transport cannot be fully explained by
this slow diffusion and a prostaglandin transporter (PGT) (Kanai
et al., 1995) and multidrug resistance protein-4 (MRP4) (Reid
et al., 2003) were found to import and export PGs, respectively.
The prostaglandin transporter is a membrane spanning protein
that is only expressed in prostanoid producing cells (Bao et al.,
2002), while MRP4 is also a membrane spanning protein but is
expressed in all cells (Russel et al., 2008).
Prostaglandin Receptors and Signaling
There are four PGE2 receptors, EP1, EP2, EP3, and EP4
(Figure 2). EP3 has several splice variants, adding an additional
functional level to the receptor (Hata and Breyer, 2004). Of these
four receptors, EP3 and EP4 have a higher affinity for PGE2
and thus require significantly lower concentration of PGE2 for
effective signaling, compared to EP1 and EP2 (Kalinski, 2012).
EP2 and EP4 mediate the anti-inflammatory and suppressive
activity of PGE2 by signaling through Gs-coupled receptors,
mediated by the adenylate cyclase-triggered cAMP/ PKA/CREB
pathway (Fujino et al., 2005). While EP2 and EP4 share the
same function, they are triggered by different concentrations of
PGE2, allowing EP2 to mediate PGE2 functions over a longer
time period and at a later stage of inflammation while EP4 is
rapidly desensitized (Nishigaki et al., 1996). Although EP2 and
EP4 signal in a cAMP-dependent manner, both have been shown
to activate the GSK3/β-catenin pathway (Fujino et al., 2002). EP4
is also capable of signaling via the ERK1/2 pathway (Fujino et al.,
2003). The signaling cascades of the EP receptors leads to the
production of cAMP or the mobilization of Ca2+ which in turn
leads to inflammation, pain, immunoregulation, mitogenesis and
cell injury. EP1 and EP3 are not dependent on Gs- coupled
receptors and lack any cAMP-activating functions. Instead, EP3
has cAMP-inhibiting functions. EP1 signals via Ca2+ release
(Hata and Breyer, 2004) while most of the splice variants of
EP3 signal via Gi-coupled PGE2 receptors and some Gs-coupled
(Sugimoto et al., 1992). The differences between the various PGE2
receptors allow for adaptable patterns and responses of various
cells types at certain stages in immunity (Kalinski, 2012). The
reader is referred to Dennis and Norris (2015)for an in-depth
review of eicosanoid signaling in infection and inflammation.
VIRAL IMMUNITY
The innate immune system is critical for pathogen recognition
(Mackay et al., 2000) and functions as the first level of defense.
In general the immune system relies upon leukocytes, antibodies,
the complement system and cytokines to remove pathogens
or toxins from the host (Janeway et al., 2004). Leukocytes are
subdivided into different types, namely neutrophils, eosinophils,
basophils, lymphocytes and monocytes which are distinguished
by their physical and functional characteristics. Of particular
importance to this review are the lymphocytes, which can be
divided into B cells, T cells and natural killer cells, as well
as monocytes which differentiate into macrophages in resident
FIGURE 2 | PGE2-EP receptor signaling pathways. Following the
synthesis of PGE2, the prostanoid is exported and signals via four known
receptors (EP1–EP4). The receptors then active cAMP/PKA/CREB signaling
pathways which are responsible for the major suppressive and regulatory
functions of PGE2. Adapted from Nasrallah et al. (2014) and Sugimoto and
Narumiya (2007).
tissues. Antibodies are produced by plasma cells (differentiated
B-cells) in response to specific antigens and bind to antigens.
They bind to antigens, before the complexes are phagocytized.
The complement system enhances the ability of antibodies and
phagocytic cells to remove pathogens and damaged cells from
an organism and promotes inflammation (Figure 3I). Although
the complement system is considered to be part of the innate
immune systems, it can be brought into action by the adaptive
immune system. The complement system is known to consist of
three components. These include, the classical pathway (relies
on the activation of C1-complex by antibodies), the alternative
pathway (relies on direct interaction between the pathogen and
C3b) and the lectin pathway (relies on binding of certain sugars
to mannose-binding lectin). Lastly, cytokines are a group of
small molecules that are important in cell signaling and some as
immunomodulatory agents. Cytokines play an important role in
the balance between humoral and cell-based immunity.
Immune defenses against viruses are initiated when
viral infection occurs or when antibodies from a previous
infection recognize the virus and neutralize it (Mackay et al.,
2000) (Figure 3A). Natural killer (NK) cells (Brandstadter
and Yang, 2011) and interferons (IFN) are the most
effective mechanism of the innate immunity against viral
infections (Figures 3B,C). Natural killers cells are particularly
important for the defense against the herpesvirus, poxvirus,
papillomavirus, cytomegalovirus, influenza A virus, and human
immunodeficiency virus (HIV) (Biron et al., 1989; Orange,
2002; Jost and Altfeld, 2013). These cells function mainly by
killing infected cells by releasing cytotoxins early in infection,
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FIGURE 3 | The interaction between the innate and adaptive immunity in the presence of pathogens. (A) Upon viral infection the infected cell presents the
viral antigen on the major histocompatibility complex (MHC)-I. (B) Cytotoxic T cells (Tc) and natural killer cells (NK) can then bind to these viral antigens and (C) lead to
the destruction of the cell. (D) Viral particles neutralized by pre-existing antibodies can be engulfed by macrophages via antibody neutralization. (E) This leads to viral
antigens being presented by dendritic cells (DC), shown in blue on MHC-ll and the resulting antigen presenting cells (APC) activating Tc and NK and releasing
cytokines. (F) T helper cells bind to these viral antigens and differentiate into Th1 or Th2 responses. T helper cells are also responsible for the activation of B cells.
(G) The B cells transform into plasma cells which start producing antibodies specific toward the antigen and differentiate into B memory cells. (H) Toll-like receptors
are an integral part of the innate immunity and function via two pathways activating NFκB, mitogen-activated kinases and type I IFN. (I). The complement system
composes of different pathways that lead to the destruction of infected cells. Adapted from Rouse and Sehrawat (2010).
preventing spread to neighboring cells (Vivier et al., 2008).
They also play a critical immunoregulatory role during the
development of adaptive immunity. Thus, NK cell-mediated
immunity plays a role in the control and clearance of viruses in
the early stages of infection, but the continual stimulation of NK
cells can contribute to viral pathology (Jost and Altfeld, 2013).
However, there is still limited knowledge about the mechanisms
of NK recognition and antiviral function. Another important
response of the innate immunity toward viral infection is IFN
(Samuel, 2001). Interferons are produced when a virus infects
a cell (Sonnenfeld and Merigan, 1979). They are secreted as
cell surface receptors causing the transcription of multitudes of
IFN-stimulated genes which encode for protein products with
antiviral, antimicrobial, antitumor and immunomodulatory
effects (Fensterl and Sen, 2009). Type I (IFN-α, -β, -ω, -ǫ, -κ, -τ,
-δ, -ν, and -ζ) and type III (IFN-λ) IFNs are induced when any
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cell recognizes PAMPs whereas type II (IFN-γ) is induced by
other cytokines like IL-12 and expression is restricted to T cells
and NK cells (Samuel, 2001; Fensterl and Sen, 2009). Viruses
have also acquired various mechanisms to circumvent these
actions of the innate immunity (Cerwenka and Lanier, 2001;
Katze et al., 2002).
Another critical role player in innate immunity is a class of
proteins called Toll-like receptors (TLRs) (Figure 3H; Xagorari
and Chlichlia, 2008). Toll-like receptors are single, membrane
spanning, non-catalytic receptors that are mainly expressed by
macrophages and DCs. They are responsible for recognizing
and responding to the PAMPs, leading to the activation of
intracellular signaling pathways and altered gene expression.
In turn, this allows the host immune system to detect
pathogens and respond to their stimuli (Kawai and Akira,
2005). The signaling pathways that are activated by TLRs are
responsible for the production of type I IFN, inflammatory
cytokines and chemokines as well as the induction of immune
responses responsible for eliminating pathogens (Kawai and
Akira, 2006). Toll-like receptors signal via two distinct pathways,
the MyD888-dependent and the TRIF-dependent pathways
(Kawai and Akira, 2010). The MyD888-dependent pathway’s
primary effect is to activate nuclear factor kappa B (NFκB) and
mitogen-activated proteins kinases, while activation of the TRIF-
dependent pathway leads to the production of type I IFN and the
transcription of NFκB. Sensing via TLRs is also responsible for
the induction of DC maturation, which in turn initiates adaptive
immune responses (Pasare and Medzhitov, 2004).
Dendritic cells and their system of antigen-presenting cells
(APC) (Figures 3D,E) are another important component of
immunity as they bridge the innate and adaptive immunity
(Banchereau and Steinman, 1998; Chan et al., 2006). The main
function of DCs are to activate naïve T cells by presenting
processed antigen material on their surface (Banchereau and
Steinman, 1998). However, before DCs can present the antigenic
material, they have to complete a maturation cycle which
is induced by either direct contact with pathogens or by
interactions with other innate immune cells. Invading pathogens
are sensed via extensive PAMP receptors which control the
secretion of cytokines, migration, proliferation, and expression of
major histocompatibility complex (MHC) II and co-stimulatory
molecules in DCs (Steinman, 2003). The activation of DCs can be
enhanced by activated NK cells (Chan et al., 2006).
The adaptive immunity’s B and T cells are stimulated by DCs
(Hess et al., 2016) (Figure 3G). B cells, which are the precursors
to antibody secreting cells, directly recognize antigens through
their B-cell receptors, while T cells are dependent on APCs
for antigen recognition (Banchereau and Steinman, 1998). In
viral infections, B cells (part of humoral immunity) begin their
maturation process when they come in contact with viral antigens
within the lymphatic system (Dörner and Radbruch, 2007).
Naïve B cells have membrane-bound antibodies that effectively
bind the viral antigen. Immediately following its contact with a
specific viral antigen the B cell divides to become B memory cells
and/or plasma cells. B memory cells express the samemembrane-
bound antibody as original naïve B cells and this is essential
for a faster immune response to the particular viral antigen in
future infections. Plasma cells also produce the same antibody
as the original B cell, but are secreted into the bloodstream
and neutralize the viral pathogen. T cells (part of cell-mediated
immunity) express T cell receptors (TCR) and either CD4+ or
CD8+ receptors (Sant and McMichael, 2012). As stated earlier,
T cells cannot recognize antigens without receptor molecules
(eitherMHC I orMHC II) which aremembrane-bound onAPCs.
T cells mature into T helper cells (TH), cytotoxic T cell (Tc), and
T regulatory cells (Tregs). T helper cells express CD4+ receptors
and are responsible for activation of Tc, B cells and other
immune cells (Alberts et al., 2002) (Figure 3F). As mentioned
earlier, TH function by producing either Th1 or Th2 responses
(Figure 3F). T helper cells 1 are produced when DCs secrete IL-
2 and IFN-γ cytokines. These Th1 cells then secrete their own
cytokines (IFN-γ and TNF-β) which stimulate recruitment of
other lymphocytes to inflammation areas, induce B cell antibody
switching and activate Tc (Romagnani, 1992).The Th1 responses
are thus essential for the removal of intracellular pathogens. T
helper cells 2 are produced when APC present antigens to TCR
along with costimulatory molecule B7, IL-4, and IL-2. T helper
cells 2 then secrete their own cytokines (IL-4, IL-5, and IL-13)
which promotes IgE production, blocks IFN-γ receptors, recruits
and activates basophil and eosinophil leukocytes (Romagnani,
1992). The Th2 response is thus responsible for the control
of extracellular pathogens. Cytotoxic T cells remove pathogens
and infected host cells and express CD8+ receptors, while Tregs
express CD4+ and CD25+ and help in distinguishing of self from
non-self-molecules (Alberts et al., 2002).
THE ROLE OF PGE2 IN INFLAMMATION
AND IMMUNITY
All the classic signs of inflammation (swelling, redness, heat,
and pain) can be attributed to PGE2 (Funk, 2001). PGE2 causes
redness and edema (of skin) by augmenting arterial dilation
and microvascular permeability, increasing the blood flow into
inflamed tissues. The pain caused by PGE2 results from the action
on peripheral sensory neurons and on central sites within the
spinal cord and brain. In addition, the binding of PGE2 to one of
its various receptors can regulate the functions of macrophages,
dendritic cells (DCs) and T and B lymphocytes (Ricciotti and
FitzGerald, 2011). These regulating functions of cell types can in
turn lead to both pro- and anti-inflammatory effects.
PGE2 also plays a role in the regulation of cytokine expression
in DCs and has shown bias in T cell differentiation toward
either Th1 or Th2 responses (Kirkpatrick, 2005) (Figure 4).
Disruption in the early stages of DC differentiation is noted as
one of the effects of PGE2 on DCs (Kalinski et al., 1997). In
addition to the suppressive function of PGE2 on differentiation
of functionally competent Th1-inducing DCs, they also suppress
responses of Tc (Obermajer et al., 2011). The induction of
the DC migratory phenotype permitting their homing to drain
lymph nodes, is enhanced by PGE2 (Kabashima et al., 2003;
Legler et al., 2006). During early maturation, PGE2 can stimulate
DCs to express co-stimulatory molecules which enhance T-cell
activation (Krause et al., 2009). PGE2 can also enhance DC
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production of suppressive factors, but the net effect on DCs
is to enhance promotion of T cell expansion (Kalinski, 2012).
Dendritic cells that havematured in the presence of PGE2 have an
impaired ability to induce Th1 while enhancing Th2 responses.
PGE2 also has suppressive effects on naïve T cell activation
and expansion as well as direct inhibitory effects on interleukin
12 (IL-12) production and the expression of IL-12 receptors
(Kalinski, 2012). Furthermore, PGE2 also balances the Th cell
responses by inhibiting interferon (IFN)-γ, a Th1 response. It
does, however, not inhibit IL-4 and IL-5, Th2 responses, in CD4+
T cells (Snijdewint et al., 1993) (Figure 4). PGE2 is responsible
for the suppression of IL-2 production and IL-2 responsiveness
in T cells, leading to the suppression of T cell activation and
proliferation at high doses (Kalinski, 2012). At lower doses PGE2
already shows a great modulatory effect on the shifting patterns
of CD4+ T cell responses form the aggressive Th1 cells toward
Th2 and Th17 cells that cause less tissue destruction. The Th1
suppressive effect of PGE2 also relies on the suppression of IL-12
in macrophages and DCs (van der Pouw Kraan, 1995; Kalinski,
2012). Thus, PGE2 shifts the immune response from Th1 to Th2,
which leads to a reduced protective ability against intracellular
pathogens (viruses and bacteria). In addition to the direct effect
of PGE2 on Th1 immune cells, recent studies have showed the
indirect effect of PGE2 in enhancing the development and activity
of suppressive types of immune cells (Kalinski, 2012). PGE2 has
been shown to promote the development of Tregs in both mice
and humans (Baratelli et al., 2005). The EP2- and EP4-dependent
induction of Tregs in murine cancer (Sharma et al., 2005) and
skin UV irradiation (Soontrapa et al., 2011), have been shown to
rely on COX-2 and PGE2. The Tregs have been shown to have
with an role in human tumor tissues (Bergmann et al., 2007),
The interaction between DCs and Tregs are also promoted by
PGE2, suggesting a role in the promotion of the expansion of pre-
existing Tregs (Muthuswamy et al., 2008). It has also been shown
the PGE2 is involved in mediating the suppressive effect of Tregs
(Mahic et al., 2006).
T helper cells 17 are important in the maintenance of
mucosal barriers and the subsequent clearance of pathogens
from these areas and have been implicated in autoimmune
disorders and infectious diseases (Zambrano-Zaragoza et al.,
2014). Cytokines such as IL-6, TGFβ, IL-21, and IL-23 are
involved in the development of Th17 cells (Holzer et al., 2013).
In addition, it has been shown that PGE2 plays a role in
the differentiation and function of Th17 cells via cAMP and
EP2/EP4 signaling (Boniface et al., 2009). Napolitani et al. (2009)
concluded that PGE2 may dramatically influence the balance
between the highly inflammatory IL-17 and the negative feedback
loop exerted by IFN-γ. PGE2 accomplishes this by triggering
the expression of EP2 and EP4 receptors on T cells, leading
to a rapid increase in retinoic-acid-related orphan receptor-γt
(controls T-cell precursors) and a decrease of T-cell specific T-box
transcription factor 21 mRNA (encodes for a Th1 cell-specific
transcription factor). The role Th17 plays in viral infection will
be discussed in detail in a later section. Although no direct link
has been found between PGE2 and autoimmune diseases, the role
of Th17 cells have been reviewed in Zambrano-Zaragoza et al.
(2014), implicating causative roles in Glioma, Multiple Sclerosis,
Type 1 Diabetes and others. Since PGE2 can play a regulatory role
in Th17 cell differentiation and functioning, it may be speculated
to have some role in autoimmune diseases.
Toll like receptor 4 is well-known for its ability to recognize
LPS and other ligands, including viral proteins, polysaccharides,
and endogenous proteins (Brubaker et al., 2015). PGE2 has
strong suppressive effects on LPS-induced IFN-β production at
mRNA and protein levels in murine J774A.1 macrophages (Xu
et al., 2008). This inhibitory effect is mediated through EP2
and EP4 which in turn activates the Epac/PI3K/Akt pathway. In
contrast, PGE2 inhibits LPS-induced TNF-α by a PKA pathway
independent of the Epac/PI3K/Akt pathway. Importantly, it was
found that blocking COX activity in vivo resulted in higher
concentrations of IFN-β post-LPS. Degraaf et al. (2014) showed
that PGE2 can decrease the expression of TLR4. The authors
showed that the effect was not by regulation of TLR4 mRNA
but rather by the inhibition of its translation. They concluded
that this reduction was mediated by EP2-dependent cAMP
activated by PKA. The reduction in TLR4 expression was enough
to decrease the transcription and section of TNF-α alveolar
macrophages in responses to LPS. This thus shows that lipid
mediators can modulate TLR4-mediated immune responses.
PGE2 can also interfere with early B cell activation and play
a cAMP-mediated role in the regulation of immunoglobulin
(Ig) class switching in B cells (Simkin et al., 1987; Phipps
et al., 1991). Antibody class switching is a process where B cells
change the production of antibodies from one type to another
by a mechanism called class switch recombination (reviewed
in Stavnezer and Amemiya, 2004). One of the most important
consequences of these effects is the promotion of IgE production
by PGE2 contributing to atopic disease (Carini et al., 1981).
Furthermore, PGE2 can also exert anti-inflammatory effects
on neutrophils, macrophages, mast cells and NK cells which
all form part of the innate immune system (Kalinski, 2012)
(Figure 4). In NK cells, PGE2 functions by suppressing the
responsiveness of IL-12 (Walker and Rotondo, 2004) and IL-
15 (Joshi et al., 2001) which suppresses the cytolytic effects of
NK cells (Bankhurst, 1982). PGE2 abrogates NK cell “helper”
function by inhibiting the ability of NK cells to produce IFN-
γ (Mailliard et al., 2005). The function of macrophages are
modulated by PGE2 in an EP2-dependent (Aronoff et al.,
2004) and phosphatase and tensin homolog-dependent manner
(Canetti et al., 2007) which limits phagocytosis by alveolar
macrophages and their pathogen-killing function (Serezani et al.,
2007). This inhibition is in part mediated by induction of IL-
1R–associated kinase-M, which blocks the scavenger receptor-
mediated phagocytosis and the TLR-dependent activation of
tumor necrosis factor-α (Hubbard et al., 2010). Furthermore,
it has been shown that PGE2 in combination with LPS can
promote anti-inflammatory phenotypes in macrophages by high
expression of IL-10 and regulatory markers, SPHK1 and LIGHT,
via a protein kinase A-dependent pathway (MacKenzie et al.,
2013). The local attraction and degranulation of mast cells are
induced by PGE2 in a mechanism involving EP1 and EP2 (Hu
et al., 1995; Gomi et al., 2000).
Various steps of inflammation can thus bemodulated by PGE2
in either a pro-inflammatory or anti-inflammatory manner.
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FIGURE 4 | Effect of PGE2 on immune responses. Prostaglandin E2 suppresses the Th1- and natural killer (NK) cell-mediated type I form of immunity at their sites
of induction, while supporting local acute inflammation and phagocyte mediated immunity. Prostaglandin E2 regulates the influx and activity of the effector vs. the
regulatory cells into affected tissues. Purple indicates effects on immune suppression; blue indicates effects on immunity against intracellular pathogens, while green
indicates effects on extracellular pathogens; ↑ increase; ↓ decrease. Interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), Immunoglobulin (Ig). Toll-like
receptors (TLRs) Adapted from Kalinski (2012).
PGE2 can also modulate the immune system by shifting Th
responses and thus affect the interplay between innate and
adaptive immunity.
VIRAL INFECTION AND PGE2
As reviewed above, PGE2 has varying effects on the immune
system. In some instances viruses can interact with PGE2 and
possibly benefit from the effects of PGE2 (Table 1). A few of the
potential effects of PGE2 on various viral infections are described:
Double-Stranded DNA Viruses
Herpes Simplex Virus
Harbour et al. (1978) showed that when African green monkey
kidney epithelial cells (Vero cells) were treated with PGE2 (0.1
to 10 µg/ml) for 24 h prior to infection by herpes simplex virus
(HSV) type I (SC.I6 strain), there was a significant increase in
the size of the plaques. When a low multiplicity of infection
(MOI) (0.1) was used, PGE2 increased the viral yield, while no
such effect was seen at high MOI (10). Furthermore, when Vero
cells were treated with PGE2 inhibitors (mefenamic acid and
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TABLE 1 | The effect of PGE2 on viral replication and infection.
Group Virus The effect of PGE2 on viral replication Reference
(I) Double-stranded
DNA viruses
Herpes simplex virus Increase viral replications Harbour et al., 1978
Cytomegalovirus PGE2 contributes to immunosuppressive effect Nokta et al., 1996
PGE2 upregulation of major immediate promotor Kline et al., 1998
COX inhibitors decrease progeny virus but the effect is
overcome by exogenous PGE2
Zhu et al., 2002
PGE2 increase plaque formation and viral DNA copy
numbers
Hooks et al., 2006
PGE2 plays a role in direct cell-to-cell spreading Schröer and Shenk, 2008
Epstein Barr virus Lytic reaction via EP signaling pathways Gandhi et al., 2015
(III) Double-stranded
RNA viruses
Rotavirus COX inhibitors reduce duration of diarrhea Yamashiro et al., 1989
PGE2 might contribute to pathogenicity Zijlstra et al., 1999
PGE2 and COX-activity essential for Wa strain infection Rossen et al., 2004
Might be required for early infection i.e. attachment Rossen et al., 2004
(IV) (+) Single-stranded
RNA viruses
Coxsackie virus Decrease viral titers Xie et al., 2012
Enterovirus 71 PGE2 might be required for replication Tung et al., 2010a, 2011; Wang
et al., 2015
Sapovirus PGE2 decreases the production of NO, leading to an
increase in PSAV
Alfajaro et al., 2017
(V) (−) Single-stranded
RNA viruses
Vesicular stomatitis virus COX inhibitors/antagonist reduced viral production but the
effect is overcome by exogenous PGE2
Chen et al., 2000
COX-2 antagonist decreased viral titers Chen et al., 2002
Influenza A virus PGE2 has an inhibitory effect on innate and adaptive
immunity in mice
Liu et al., 2012
PGE2 induces pro-inflammatory genes Coulombe et al., 2014
PGE2 activates expression of IL-27 Park et al., 2016
Parainfluenza 3 virus PGE2 inhibits viral replication Luczak et al., 1975
Lymphocytic choriomeningitis virus PGE2i ihibits the survival and effector functions of Tc Chen J. H. et al., 2015
Respiratory syncytial virus PGE2 causes a delayed protective RSV specific immune
response
Bartz et al., 2002
COX inhibitors reduced PGE2-dependent RNA transcription Liu et al., 2005
(VI) Single-stranded
RNA-RT viruses
Human T-lymphotropic virus type lll PGE2 causes an increased production of virus Kuno et al., 1986
Human immunodeficiency virus PGE2 enhances HIV-1 long terminal repeat mediated
reporter gene activation
Olivier and Tremblay, 1998
PGE2 decreases virion penetration by suppressing
expression of CCR5
Thivierge et al., 1998
PGE2 inhibits virus replication by protein kinase A
-dependent mechanism
Hayes et al., 2002
PGE2 has an immunosuppressive effects when co-infected
with HPV
Fitzgerald et al., 2012
PGE2 reduces cell-to-cell spreading Clemente et al., 2014
PGE2 could play a role in pathogenicity via Th17 cell
regulation
Zambrano-Zaragoza et al., 2014
(VII) Double-stranded
DNA-RT viruses
Hepatitis B virus PGE2 results in loss of viral replication Flowers et al., 1994
PGE2 decreases viral antigen Hyman et al., 1999
PGE2 could play a role in pathogenicity via Th17 cell
regulation
Yang et al., 2013
indomethacin) there was a decrease in plaque size and inhibition
of viral replication at a low MOI. This inhibitory effect can be
overcome by the addition of exogenous PGE2. Taken together the
results indicate that PGE2 does not increase viral production, but
rather enhances the spread of the virus between cells. Work done
by Thiry et al. (1985) on bovine herpes virus 1 (IBR/Cu5 strain) in
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Georgia bovine kidney cells (GBK cells) also showed an increase
in the mean plaque size when GBK cells were treated with 0.1 and
10 µg/ml of PGE2. Treatment of HSV-tk (herpes simplex virus
thymidine kinase)-transduced MC38 (murine colon cancer) cells
with sulfasalazine (a NFκB inhibitor) lead to the inhibition
of NF-κB activity, inhibitor-κB phosphorylation and nuclear
translocation of NF-κB (Konson et al., 2006). This significantly
decreased COX-2 expression and in turn reduced PGE2 release.
In addition, these authors found that HSV-tk-transduced 9L
(rat gliosarcoma) and T24 (human urinary bladder cancer) cells
enhanced the expression of COX-2 and significantly increased
PGE2 levels. When 4T1 (mouse mammary tumor cells) cells
were infected with OSVP (a murine 15-PGDH inserted into the
OSV viral genome) expression cassette) there was a significant
decrease in PGE2 accumulation which led to the alleviation of
immune suppression in mice (Walker et al., 2011). It can thus
be concluded that PGE2 plays a role in HSV infection, although
the exact mechanisms by which it facilitates viral replication and
release are yet to be elucidated.
Cytomegalovirus
The infection of human T lymphocyte cells (MO cells) with
cytomegalovirus (CMV) (AD169 strain) was found to induce
the release of PGE2 via a TNF-α-dependent pathway (Nokta
et al., 1996). This release of PGE2 apparently contributes to the
immunosuppressive effects of CMV and could be involved in
the pathogenesis of CMV. Kline et al. (1998) found that PGE2
can upregulate the major immediate promotor of human CMV
(HCMV). They postulated that PGE2 could directly activate this
promoter. Monocytoid cells (THP-1) were transfected with a
plasmid containing the major immediate promoter gene and
subsequently stimulated with PGE2. A synergistic increase in the
promoter’s activity was seen for PGE2 and other cytokines (IL-
1β, TNF-α, IL-6, and IL-10). Human CMVmay thus be activated
by a mechanism which involves the activation of macrophages by
these cytokines. The inhibition of COX-2 blocks the replication
of HCMV, but when PGE2 is added exogenously the yield of
infectious virus is substantially restored (Zhu et al., 2002). Hooks
et al. (2006) showed that retinal pigment epithelial (RPE) cells
infected with CMV induced COX-2mRNA and protein synthesis
increasing PGE2 levels. The increased levels of PGE2 enhanced
CMV plaque formation and CMV DNA copy numbers. This
indicates that PGE2 is required for the effective replication
of HCMV, although the molecular mechanisms are yet to be
elucidated. The treatment of CMV infected primary human
foreskin fibroblast (HFF) with tolfenamic acid and indomethacin
(inhibitors of COX) drastically reduced the direct cell-to-cell
spread of CMV (Schröer and Shenk, 2008). The effect of these
inhibitors is reversed by the addition of PGE2. This indicates that
PGE2 is required for the effective replication of HCMV, although
the molecular mechanisms are yet to be elucidated.
Epstein Barr Virus
Gandhi et al. (2015) investigated the link between chronic
inflammation and the induction of Epstein Barr virus (EBV) lytic
reactivation. They found that the addition of lipopolysaccharides
(LPS) to cells latently infected with EBV, upregulated the
expression of COX-2 and increased PGE2. The elevated levels of
COX-2 and PGE2 coincided with gp350 (EBV late lytic protein)
synthesis and detection of EBV in cell culture supernatant. When
NS-398 (COX-2 inhibitor) was added to the cells, there was a
drastic decrease in the levels of virus detected in cell culture
supernatant. The overexpression of COX-2 and PGE2 in infected
cells also coincided with the overexpression of PGE2 receptors
EP1 and EP4. The addition of chemical inhibitors of EP1 and
EP4 reduced the lytic reactivation of EBV even when COX-2
levels were upregulated. Taken together these results indicate that
COX-2 is responsible for the lytic reactivation of EBV via PGE2
and its signaling via EP1 and EP4 receptor.
Double-Stranded RNA Viruses
Rotavirus
Studies in infants found that there was an increase in PGE2
in both stool and plasma during rotavirus (RV) infection
(Yamashiro et al., 1989). When these children were treated with a
COX-inhibitor there was a reduction in the duration of diarrhea.
Rotavirus infection also upregulates expression of both MHC I
and MHC II in piglets (Zijlstra et al., 1999). Increases of CD8+
and CD4+ T-lymphocyte numbers were observed in the jejunum
of piglets as well as elevated levels of PGE2. These observations
suggested that PGE2 might contribute to RV pathogenicity. In
2009 Rodríguez and co-workers infected human Caucasian colon
adenocarcinoma cells (Caco-2 cells) with RV and showed that the
immunomodulators, IL-8, PGE2, and small quantities of TGF-
β1, were released in RV infection Rodríguez et al. (2009). These
immunomodulators are known to shift the T cell response to Th2
and may in part be responsible for the low number of T-cells in
blood samples during RV infection. Infection of cells with RV
is significantly inhibited when cells are treated with peroxisome
proliferator-activated receptor gamma (PPARγ) and NSAIDs,
indicating that RV has pro-inflammatory actions (Guererero
et al., 2012). Moreover, PGE2 and COX-activity were shown to
be essential for the establishment of RV (Wa strain) infection
in Caco-2 cells (Rossen et al., 2004). Peroxisome proliferator-
activated receptor gamma is responsible for the regulation of fatty
acid storage and glucose metabolism. This inhibitory effect on
RV indicates that fatty acids and their downstream products, like
eicosanoids, may play a role in RV infection as it is well-known
that RV associates with lipid droplets which is crucial for RV
replication (Cheung et al., 2010). Rossen et al. (2004) postulated
that PGE2 is necessary for early infection, most likely in viral
protein synthesis and progeny production, rather than viral
RNA production. The exact pathways behind these mechanisms
remain unknown. It appears as if RV requires pro-inflammatory
signaling for efficient replication, and that viral replication
is inhibited by anti-inflammatory treatment (Guerrero and
Acosta, 2016). There is a still a major gap in understanding
the molecular mechanisms behind RV-induced inflammatory
signaling.
(+) Single-Stranded RNA Viruses
Coxsackie Virus
Henke et al. (1992) showed that when human monocytes are
infected with Coxsackie virus (B3 strain) (CVB3) they become
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activated and secrete cytokines. Higher levels of PGE2 and
TNF-α were detected via ELISAs in infected cells compared
to the uninfected cells. In 2011, Xie and co-workers showed
that when anti-mouse IL-17antibody was added to block IL-
17A (cardiac tumor-necrosis factor alpha) in BALB/c mice
there was an increase in COX-2 proteins and PGE2 as well
as a decrease in transforming growth factor beta (TGF-β) and
TNF-α Xie et al. (2012). This was followed by a reduction
in viral titers and decreased pathological scores. They also
indicated that PGE2 and COX-2 play a role in viral myocarditis
by being upregulated by IL-17A and TNF-α. The exact
mechanistic role of these factors on CVB3 infection is yet to be
elucidated.
Enterovirus 71
When rat brain astrocytic (RBA-1) cells are infected with
enterovirus (strain 71) (EV71) they induce the expression
of COX-2 and the subsequent release of PGE2 via c-
Src/PDGFR/PI3K/Akt/p42/ p44 MAPK/c-Jun and NF-κB
cascades (Tung et al., 2010b). Tung et al. (2010b) showed that
human neuroblastoma (SK–N–SH) cells infected with EV71
also induced the expression of COX-2 and the production of
PGE2 via a MAPKs (p42/p44 MAPK, p38 MAPK and JNK)
and observed that the increase in PGE2 generation might be
required for EV17 replication in infected cells. They postulated
that EV17 replication by this COX-2/PGE2 mechanism may
have an effect on the pathogenesis of central nervous system
diseases. In 2011 Tung and co-workers found that the activation
of the cAMP response element binding protein (CREB) in
addition to the role of the c-Src/EGFR/p42/p44 MAPK signaling
pathway in SK–N–SH cells were essential for EV71-induced
COX-2 protein expression, COX-2 mRNA synthesis, and PGE2
production. They also found that PGE2 promoted further
viral infection through EP2/EP4 receptors-cAMP signaling.
Formononetin has been shown to reduce RNA and protein
synthesis of EV71 in a dose dependent manner (Wang et al.,
2015). This reduction was due to the inhibiting effects of
formononetin on EV71-induced COX-2 expression and PGE2
production via the MAPKs pathway, including ERK, p38,
and JNK.
Sapovirus
Alfajaro et al. (2017) showed that porcine kidney cells (LLC-
PK) infected with porcine sapovirus (PSaV) Cowden strain, lead
to an increase in the amount of COX-2 mRNA and protein
levels while only transiently increasing the levels of COX-1.
The authors also showed that the blocking of COX-1 and
COX-2, by either NSAIDs or siRNAs, lead to a significant
decrease in PGE2 and subsequently a decrease in the replication
of PSaV. The viral proteins (VPg and ProPol) was found
to be associated with activation of the COXs/PGE2 pathway.
Furthermore, they observed that pharmacological inhibitors of
COX-2 lead to a drastic increase in the production of NO,
which lead to the reduction in PSaV replication that could
be restored by inhibiting nitric oxide synthase via N-nitro-L-
Methyl-Arginine-ester. The experimental data show that the
sapovirus replication cycle depend or rely on the interaction with
PGE2.
(−) Single-Stranded RNA Viruses
Vesicular Stomatitis Virus
Chen et al. (2000) found that when Chinese Hamster Ovary
(CHO) cells, infected with vesicular stomatitis virus (VSV)
(Indiana serotype), were treated with aspirin, indomethacin
(COX inhibitors) and celecoxib (COX-2 antagonist) there was
an inhibitory effect on VSV propagation. They also found an
increase in NO, a known inhibitor of VSV. Furthermore, when
PGE2 was added to the cultures there was a significant decrease
in NO and increase in viral yield. This indicates that the
products of COX have an antagonistic effect on NO production
which is in part responsible for the increase of VSV. Studies
in mice (specific pathogen-free male BALB/c AnTac) by Chen
et al. (2002) found that inhibition of COX-2 favors the Th1
response which lead to increased expression of nitric oxide
synthase (NOS) -1 and that PGE2 also effects NOS. In addition
they indicated that PGE2 might induce protein inhibitor of
NOS (PIN) which binds to NOS-1 and prevents its activity.
This indicates that PGE2 has a definite role in the propagation
and infectivity of VSV, possibly through induction of PIN
expression.
Influenza A Virus
Influenza A virus (IAV) hyper induces the COX-2 and PGE2
production (Liu et al., 2012). The accumulation of PGE2 then
activates a PKA-CREB signaling pathway, which in turn activates
the IL-27/EB13 promotor, leading to the expression of IL-
27. Interleukin-27 is responsible for the activation of signal
transducer and activator of transcription 1 (STAT1) and STAT2
which inhibits viral replication (Owaki et al., 2008). Coulombe
et al. (2014) showed that PGE2 has an inhibitory effect on
both the innate and adaptive immunity when mice (C57BL/6,
Taconic 4175, and Rag1−/−) were infected with IAV (A/Puerto
Rico/8/34). PGE2 inhibited the recruitment and activities of
macrophages via both EP2 and EP4. This had inhibitory actions
on the type l IFNs and apoptosis pathways. The suppression of
PGE2, via genetic ablation ofmPGES-1 or by the pharmacological
inhibition, improved survival after IAV infection, while the
addition of PGE2 reversed this effect. They also showed that PGE2
inhibited T cell mediated immunity and thus concluded that IAV
hijacks the mPGES-1/PGE2 pathway to suppress both innate and
adaptive immunity in an IFN dependent manner. In 2016 Park
and co-workers showed that the inhibition of mPGES-1 had anti-
influenza effects by inhibiting PGE2 production and suppressing
the induction of pro-inflammatory genes (TNF-α, IL-8, CCL5,
and CXCL10). This anti-influenza effects was reversed by the
addition of exogenous PGE2. The specific mechanism(s) used
by IAV to increase PGE2 and evade antiviral responses remain
unknown.
Parainfluenza 3 Virus
Luczak et al. (1975) showed that addition of PGE2 concentrations
of 0.1–10 µg/ml to parainfluenza 3 (PIV3) virus infected WISH
cells, inhibited the replication of PIV3. They observed that the
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effect was the most prominent when PGE2 was present in the
media throughout the replication cycle, compared to PGE2 being
added before infection and 2 h post-infection. They postulated
that PGE2 may affect the replication of PIV3 by influencing the
growth of WISH cells.
Lymphocytic Choriomeningitis Virus
It has been shown that PGE2 can impair the survival and effector
functions of Tc during chronic lymphocytic choriomeningitis
virus (LCMV) infection (Chen J. H. et al., 2015). When PGE2
signaling was blocked either directly (deletion of EP2 and
EP4) or systemically (deletion of mPGES-1 or COX inhibitors)
there was an increase in antigen specific Tc numbers and
cytokine production. Chen J. H. et al. (2015) also found
that the simultaneous inhibition of PGE2 and PD-1 signaling
(programmed cell death signaling) during LCMV infection
increased the numbers, function and viral control of Tc. They
concluded that the comodulation of PGE2 and PD-1 signaling
could be a therapeutic avenue in the treatment of certain chronic
diseases.
Respiratory Syncytial Virus
Macrophages and DCs from newborns were infected with
respiratory syncytial virus (RSV) and showed an increase in IL-
10, IL-11, and PGE2 generation (Bartz et al., 2002). These authors
concluded that PGE2 and the cytokines might contribute to the
predominance of Th2 being produced by DCs during ongoing
RSV infection. This in turn could explain the delayed protective
RSV specific immune response. In 2005 Liu and co-workers
showed that PGE2 is produced by human alveolar type II-like
epithelial (A549) cells infected with RSV and that it is required
for viral replication. They found that RSV infection induces a
time-dependent increase in both COX-2 mRNA expression and
protein synthesis and thus leads to the enhanced production of
PGE2. Furthermore, when PGE2 production was inhibited by
blocking COX-2 or cPLA2 activation, there was a significant
reduction in RSV replication. They concluded that the reduction
in RSV infection is partly due to a significant inhibition of
RNA transcription. Walsh et al. (2016) showed that ibuprofen (a
NSAID) can decrease PGE2 production during RSV infection in
5 to 6 week-old outbred pre-ruminant bottle-fed Holstein bull
calves. The decrease in PGE2 production in turn modulated the
immune responses and improved clinical outcomes. However,
they also found that treatment with ibuprofen did not affect
lung histopathology and lead to increased viral shedding. They
concluded that RSV should thus be treated with both antivirals
and immunodulators.
Single-Stranded RNA-RT Viruses
Human T-Lymphotropic Virus Type lll
Kuno et al. (1986) investigated the direct effects of PGE2
on a T-cell line (MT-4 cells) when infected with type III
human T-lymphotropic virus (HTLV-III) as well as on HTLV-
III continuous-producer cells (Molt-4/HTLV-III cells). They
found that PGE2 enhanced the production and release of
infectious virus in a dose-dependent manner. They concluded
that PGE2 or its metabolites may play a role in the activation of
transcription/translation of HTLV-III integrated genes or in the
maturation of infectious viral particles. It is unclear if PGE2 plays
any role in early infection before the integration of HTLV-III
genes.
Human Immunodeficiency Virus
In 1998 Olivier and Tremblay showed that PGE2 had a
upregulating effect on the long terminal repeat (LTR) gene of
human immunodeficiency virus type-l (HIV-l) in Jurkat E6.1
cells. HIV-1 protein expression is driven by HIV-1 LTR. They
found that this activation of HIV-1 by PGE2 was transduced via
both, NFKβ-dependent and –independent, signaling pathways.
It was concluded that the secretion of PGE2 by macrophages in
response to infection or inflammatory activators could induce
signaling pathways that results in the activation of proviral DNA
present in T cells latently infected with HIV-1. When PGE2
is added to macrophages 24 h prior to infection with HIV-1
the cells show resistance to infection (Thivierge et al., 1998).
The increase in PGE2 leads to increased cAMP levels which
in turn downregulate the expression of CCR5 (coreceptor for
HIV-1 entry). This inhibitory effect has also been observed
in the replication of both M- tropic HIV-1BAL and HIV-1 in
monocyte-derived macrophages (MDM) and monocytic cell line
(UI), respectively (Hayes et al., 2002). The inhibition appears
to rely on the cAMP/PKA-dependent mechanism and functions
at a gene expression level decreasing HIV mRNA. Hayes et al.
(2002) demonstrated that the regulation of inhibition by the
cAMP/PKA-dependent mechanism is through HIV-1 promoter
activity. Women infected with human papillomavirus and HIV-
1 showed an increase in cervical COX-2 and elevated systemic
PGE2 levels (Fitzgerald et al., 2012) which may account for
the immunosuppressive effects observed in infected patients.
Samikkannu et al. (2014) showed that AA and its metabolites
and accompanying enzymes (PGE2 and COX-2, respectively)
mediate the accelerative effect of cocaine on HIV infection
by impairing possible immune functions. PGE2 can also act
in the late stages of HIV-1’s viral cycle (Clemente et al.,
2014).Treatment with PGE2 increased the activity of Rab1
(molecular switches that regulate membrane traffic), decreased
RhoA (associated with cytoskeleton regulation) activity, and
subsequently reduced the polymerization of actin. Furthermore,
viral assembly platforms enriched with group-specific antigen
(Gag) were disrupted. Taken together these results led Clemente
et al. (2014) to conclude that PGE2 reduces the infectivity of HIV-
1 by affecting the spread of virions from cell-to-cell. In addition
Zambrano-Zaragoza et al. (2014) suggested that Th17 cells and
the Th17/Treg balance could maintain HIV under control and
could therefore play a role in the disease progression of AIDS
(Brandt et al., 2011). The ratio of Treg/Th17 showed a negative
correlation to viral plasma load (Chevalier et al., 2013), although
Treg cells correlated positively with viral load before antiviral
therapy (He et al., 2012). Antiretroviral treatment normalizes this
ratio in HIV patients (Brandt et al., 2011; He et al., 2012). Thus,
PGE2 appears to have both an inhibitory and stimulatory effect
on the replication of HIV-1 depending on specific conditions and
could play a role in HIV pathogenicity via the regulation of Th17
cells.
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Double-Stranded DNA-RT Viruses
Hepatitis B Virus
The treatment of recurrent hepatitis B virus (HBV) infection
after orthotopic liver transplantation with PGE2 has had some
beneficial effects (Flowers et al., 1994). PGE2, given intravenously,
followed by oral therapy, arrested or ameliorated recurrent
infection in 67% of treated patients. Flowers et al. (1994)
speculated that the mechanism of PGE2 interference might rely
on its ability to stabilize cellular membranes and inhibit HBV
binding and replication. Hyman et al. (1999) also showed that
PGE2 has a beneficial effect on chronic HBV, but no effect on
chronic hepatitis C (HCV). Patients were treated with PGE2
for 6 months and 47% of patients suffering from chronic HBV
showed a decrease in HBV viral parameters [serum HBV DNA
and HBeAg (envelope antigen of hepatitis B)]. In 2009, Xie and
co-workers found that celecoxib (COX-2 inhibitor) had potent
inhibitory effects on the growth of hepatitis B virus X protein
positive hepatocellular carcinoma cells (HepG2-X) (Xie et al.,
2009). When exogenous PGE2 was added to HepG2-X cells the
inhibitory effect of celecoxib was slightly overcome. The exact
beneficial mechanism of PGE2 is still unknown. T helper 17
cells as well as the ratio of Treg/Th17 appear to have a crucial
role in the occurrence, development and outcome of HBV (Sun
et al., 2012; Xue-Song et al., 2012). Interleukin 17 (cytokine
of Th17 cells) has been shown to be indispensable for HBVs
antigen (HBsAg)-stimulated differentiation of CD4+ cells into
Th17 (Yang et al., 2013). Thus, Th17 cells have been show to
participate in the pathogenesis of liver damage associated with
HBV (Yang et al., 2013). It could, thus, be plausible that levels of
PGE2 may play a role in the pathogenicity of HBV via Th17 cell
differentiation.
PROSTAGLANDIN E2 AS A POTENTIAL
THERAPEUTIC TARGET
The current review highlights the potential of the biosynthetic
pathway of PGE2 (Figure 1) as a therapeutic target in viral
infections. This is possible as PGE2 has been shown to
play a role in various viral infection, by either having a
stimulatory/inhibitory effect on the viral life cycle or host’s
immune system.
One of the first potential therapies is limiting the amount of
AA (or FA that can be converted to AA) that is taken in up in the
diet of an individual (Calder, 2005, 2010). This can be done by
limiting the amount of n-6 polyunsaturated fatty acids (PUFAs)
(vegetable oils, animal sources) and rather ingesting n-3 PUFAs
(fish oils, marine sources) which are preferentially converted
into either docosahexaenoic acid (DHA) or eicosapentaenoic acid
(EPA). They act by replacing AA as an eicosanoid substrate and
inhibiting AA metabolism (directly) or altering the effects of
inflammatory genes through effects on transcriptional activation
(indirectly) (Calder, 2005). Although EPA also gives rise to
eicosanoids, these have anti-inflammatory effects in contrast to
AA-derived eicosanoids (Calder, 2006).
Both of the COX isoforms can also serve as a potential target
as they are directly responsible for the downstream production
of PGE2. Of the two isozymes, COX-2 is a more attractive
target as COX-1 is constitutively expressed and particularly
important in gastrointestinal protection (Hawkey, 2001). This
means that COX-2 selective drugs are required to regulate the
production of PGE2. These drugs include coxibs (celecoxib
and rofecoxib), etodalac, meloxicam, and nimesulide. Coxibs
function by binding to side pockets close to the COX-2 active
site, while etodalac, meloxicam and nimesulide bind in the active
site (Jackson and Hawkey, 2000). All of these selective inhibitors
have some side effects and can only partially inhibit PGE2
production.
The next possible therapeutic targets include the PGES
(Murakami and Kudo, 2006). Microsomal prostaglandin E
synthase-1 is the most promising target as the deletion of
mPGES-1 in animal and cells models leads to no severe adverse
effects (Chen Y. et al., 2015). There are no known mPGES-
1 inhibitors due to the fact that compounds are not stable
or effective in cellular assays or animal models. The search
for an appropriate inhibitor is further complicated by specific
differences in rodent and human models as they differ in key
amino acid residues of mpGES-1 active site. Inhibitors also need
to overcome the challenge of the complex binding mechanisms
of both cofactors and substrates. Although all of these enzymes
are potential therapeutic targets, care should be taken in the way
these targets are inhibited as several of the downstream products
of the of the PGE2 biosynthetic pathway are required for normal
physiological functioning. The effect of the target should also take
into account the effect that lowering/increasing PGE2 level may
have on preexisting autoimmune conditions or in causing such
conditions.
CONCLUSIONS
In response to viral infections the host elicits a defense
by activating inflammation and immunity. The activation of
inflammation by viral infections leads to the production of PGE2
which has a modulatory role in immunity and other roles in
normal cell physiology. In this review, viruses from specific
classes including, double-stranded DNA viruses (HSV, CMV,
EBV, MAV-1), double-stranded RNA viruses (RV), (+) single-
stranded RNA viruses (CVB3, EV71, PSaV), (−) single-stranded
RNA viruses (VSV, IVA, PIV3, LCMV, RSV), single-stranded
RNA-RT viruses (HTLV-III and HIV-l) and double-stranded
DNA-RT viruses (HBV) and their interaction with PGE2 were
reviewed. PGE2 had either an inhibitory, stimulatory or in some
cases a dual role in there viral replication cycles. The stimulation
of viral pathogenicity (HSV, CMV, EBV, RV, CVB3, EV71, PSaV,
VSV, LCM, RSV, and HTLV-III) occurred mainly by affecting
the host immunity, viral transcription/translation, and/or viral
replication, while the inhibition (PIV3 and HBV) affected viral
replication itself. In the case of both IAV and HIV-1, PGE2 was
shown to have both a stimulatory and inhibitory effect. Both
these viral stimulations were dependent on immune suppression
and gene expression, while the inhibitory effects were dependent
on IL-27 expression (IAV) and inhibition of spreading (HIV-1).
In many of the viral infections the effect of PGE2 was negated
when inhibitors of PGE2 synthesis was added, but the effects
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were overcome by the addition of exogenous PGE2. Interestingly,
it appears that Th17 cells have a regulatory role in retrovirus
infections. In turn Th17 cells are regulated by PGE2 which might
play an indirect role in these viral infections. There are a number
of possible therapeutic targets in the PGE2 biosynthetic pathway,
although more research into their effects and modes of actions
are required. This paper suggest that it may be possible to design
therapeutic strategies to target selective pathways in an effort to
attenuate inflammation associated with virus infection.
When looking into the majority of studies included in this
review, the effect that PGE2 has in viral infections seem to have
been a coincidental discovery and not the primary objective of
these studies. In some cases the discovery was noted, but not
further investigated. There is, therefore, a major gap in our
knowledge of the exactly role of PGE2 in viral infections. These
gaps include, determining the exact signaling pathways that
viruses might use to induce PGE2, the role that PGE2 can play
in the induction of autoimmunity and clarifying the dependence
of viral infections of PGE2. The underlying mechanisms should
be further investigated to determine if viruses require PGE2 to
enhance their pathogenicity or require PGE2 for optimal viral
replication. Furthermore, light should be shed on the possible
effect that the interplay between TLRs, PGE2 and its receptors
may have on viral infections. Taken together these mechanisms
could also shed light on other host-pathogen interactions and
may facilitate selection or development of the more optimal
therapies against viral infections.
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